文献类型：期刊文献

英文题名：Efficacy and safety of combining commercial Chinese polyherbal preparation with conventional medicine in the treatment of coronary microvascular disease: a systematic review and network meta-analysis

作者：Guo, Xiaoying[1,2,3,4];Li, Qianrong[2,3,4];Jiang, Hugang[2,3,4];Ren, Chunzhen[2,3,4];Shu, Chang[2,3,4];Zhao, Xinke[2,3,4,5];Li, Yingdong[2,3,4]

第一作者：郭晓蓥;Guo, Xiaoying

通信作者：Li, YD[1];Li, YD[2];Li, YD[3]

机构：[1]Gansu Univ Chinese Med, Teaching Expt & Training Ctr, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou, Peoples R China;[3]Gansu Prov Key Lab Chinese Med Prevent & Treatment, Lanzhou, Peoples R China;[4]Natl Hlth Commiss Peoples Republ China, Natl Adm Tradit Chinese Med, Key Specialized Cardiovasc Lab, Key Clin Specialty, Lanzhou, Peoples R China;[5]Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou, Peoples R China;[2]corresponding author), Gansu Prov Key Lab Chinese Med Prevent & Treatment, Lanzhou, Peoples R China;[3]corresponding author), Natl Hlth Commiss Peoples Republ China, Natl Adm Tradit Chinese Med, Key Specialized Cardiovasc Lab, Key Clin Specialty, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;

年份：2026

卷号：17

外文期刊名：FRONTIERS IN PHARMACOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001796204200001)】；

基金：The author(s) declared that financial support was received for this work and/or its publication. This work was fnancially supported by the Gansu Jiaoyu Jiebang Guashuai Project (No. 2021 jyjbgs-03), National Natural Science Foundation of China (NO. 82360926,82374279), Gansu Provincial University Teachers ' Innovation Fund Project in 2025 (No.2025B-126), Scientific Research and Innovation Fund Project of Gansu University of Chinese Medicine in 2023 (No.2023KCYB-13), Lanzhou Science and Technology Plan Project in 2025 (No.2025-5-128). The funding bodies had no role in the design of the study, collection, analysis, and interpretation of data, or in writing the manuscript.

语种：英文

外文关键词：commercial Chinese polyherbal preparation; conventional medicine therapy; coronary microvascular disease; network meta-analysis; randomized controlled trial

摘要：Objective: To systematically assess and compare the efficacy and safety of 19 commercial Chinese polyherbal preparation for coronary microvascular disease (CMVD) through a frequentist network meta-analysis (NMA) of randomized controlled trials. Methods: A comprehensive search was performed across multiple databases through November 2025 to identify studies evaluating the effectiveness of CCPPs in treating CMVD. Two independent reviewers screened studies, extracted data, and assessed risk of bias. The NMA was conducted using a frequentist random-effects model, and statistical analyses were performed in Stata 18.0. Network diagrams, league tables, and SUCRA (surface under the cumulative ranking curve) plots were generated to compare and rank the treatments. Results: Sixty-seven randomized controlled trials (RCTs) involving 6,139 patients were included. All CCPPs combined with conventional medicine (CM) demonstrated potential advantages in efficacy compared to CM alone, but the optimal agent is highly outcome-specific. Yixinshu Tablets may be more favorable for improving microvascular function by reducing the index of microcirculatory resistance (IMR) and increasing coronary flow reserve (CFR). Tongxinluo Capsule showed a relatively greater reduction in corrected thrombolysis in myocardial infarction frame count (cTFC) and a higher total effective rate in the included studies. Shexiang Tongxin Dripping Pills was associated with a more pronounced elevation in left ventricular ejection fraction (LVEF). Danshen Dripping Pills ranked highest for reducing endothelin-1 (ET-1) and increasing nitric oxide (NO) levels. Yindan Xinnao Tong Capsules exhibited a relatively greater decrease in high-sensitivity C-reactive protein (hs-CRP). Additionally, Shexiang Baoxin Pills was associated with the lowest risk of adverse events. Conclusion: The combination of CCPPs with CM for CMVD may be associated with improved clinical outcomes compared to CM alone. However, these initial results require confirmation through high-quality, rigorously designed clinical trials.